Targeting Novartis’ Scemblix, Enliven lays out case for leukemia drug in early results

Enliven Therapeutics released new Phase 1 data for its chronic myeloid leukemia program (CML) it hopes can eventually compete with Novartis’ Scemblix.

The experimental therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal

LONDON — The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals, which is developing treatments for neurological diseases, in a deal worth

October 14, 2024

PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000 | Psychedelic Invest

PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC: PMBHF), a biotechnology company focused on the research, development and manufacturing MDXX class molecules (including MDMA), is

June 14, 2023

EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.